Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potassium Chloride for Refractory Ventricular Fibrillation in OHCA
NCT04316611Phase 2Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of potassium chloride in cardiac arrest (SCA) and ventricular fibrillation (VF), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Survival at hospital admission at 1 day. Planned start Dec 2023; status: withdrawn.
02
Drugs
potassium chloride
03
Conditions
cardiac arrest (SCA)ventricular fibrillation (VF)
Beyond the preview
Go deeper on NCT04316611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316611.